ACI Formulations PLC

3rd Quarter Ended Report 2025-26
For the nine months ended on 31 March 2026

ACI Formulations PLC

Statement of financial position
Unaudited

Figures in "000"

In Taka	Note	As at 31 March 2026	As at 30 June 2025
Assets			
Property, plant and equipment	5	2,796,608	2,662,168
Right-of-use assets		21,668	23,291
Investments	6	83,905	83,552
Non-current assets		**2,902,181**	**2,769,011**
Inventories	8	1,563,765	1,469,898
Trade receivables	9	2,147,294	1,318,352
Other receivables		159,748	64,258
Inter-company receivables	10	1,913,348	2,050,805
Advances, deposits and prepayments	11	157,907	202,043
Current tax assets		488,341	486,847
Cash and cash equivalents		42,905	242,556
Current assets		**6,473,308**	**5,834,760**
Total assets		**9,375,489**	**8,603,771**
Equity			
Share capital		472,500	472,500
Revaluation reserve		1,475,889	1,475,889
Retained earnings		1,886,208	1,618,503
Total equity		**3,834,598**	**3,566,892**
Liabilities			
Employee benefits	12	54,976	67,965
Lease liabilities		28,701	29,331
Deferred tax liabilities		198,876	199,583
Non-current liabilities		**282,553**	**296,879**
Bank overdrafts		124,854	245,034
Loans and borrowings		4,055,920	3,643,054
Lease liabilities- current portion		21,527	13,157
Trade payables		117,806	163,427
Other payables	13	914,343	651,258
Unclaimed dividend account	14	2,044	1,699
Inter-company payables	15	21,843	22,372
Current liabilities		**5,258,338**	**4,740,000**
Total liabilities		**5,540,891**	**5,036,879**
Total equity and liabilities		**9,375,489**	**8,603,771**
Net asset value (NAV) per share		**81.16**	**75.49**

Managing Director **Director** **Chief Financial Officer** **Company Secretary**

ACI Formulations PLC

Statement of profit or loss and other comprehensive income
Unaudited

Figures in "000"

In Taka	Note	For the nine months ended from July 2025 to March 2026	For the nine months ended from July 2024 to March 2025	For the 3rd quarter ended from January 2026 to March 2026	For the 3rd quarter ended from January 2025 to March 2025
Revenue	16	**4,521,602**	4,121,201	**1,358,339**	1,299,297
Cost of sales	17	**(3,090,553)**	(2,737,639)	**(951,163)**	(907,509)
Gross profit		**1,431,049**	1,383,562	**407,176**	391,788
Administrative, selling and distribution expenses	18	**(767,227)**	(648,903)	**(258,400)**	(226,475)
Other income	19	**61,551**	38,521	**24,195**	5,329
Operating profit		**725,373**	773,180	**172,971**	170,643
Finance costs,net		**(189,083)**	(210,543)	**(67,294)**	(57,705)
Profit before contribution to WPPF		**536,290**	562,637	**105,678**	112,938
Contribution to WPPF		**(26,814)**	(28,132)	**(5,283)**	(5,647)
Profit before tax		**509,476**	534,505	**100,395**	107,291
Tax expenses		**(123,645)**	(128,063)	**(18,451)**	(18,433)
Profit after tax		**385,830**	406,442	**81,944**	88,857
Other comprehensive income		**-**	-	**-**	-
Total comprehensive income		**385,830**	406,442	**81,944**	88,857
Earnings per share					
Basic earnings per share (EPS)		**8.17**	8.60	**1.73**	1.88

Managing Director **Director** **Chief Financial Officer** **Company Secretary**

ACI Formulations PLC

Statement of changes in equity
Unaudited

Figures in "000"

	For the nine months ended 31 March 2026			
	Attributable to owner of the Company			
In Taka	**Share capital**	**Revaluation reserve**	**Retained earnings**	**Total**
Balance at 1 July 2025	**472,500**	**1,475,889**	**1,618,503**	**3,566,892**
Total comprehensive income				
Profit for the period	-	-	**385,830**	**385,830**
Total comprehensive income	-	-	**385,830**	**385,830**
Transactions with owners of the company	-	-	-	-
Contributions and distributions				
Dividends	-	-	**(118,125)**	**(118,125)**
Total transactions with owners of the company	-	-	**(118,125)**	**(118,125)**
Balance at 31 March 2026	**472,500**	**1,475,889**	**1,886,208**	**3,834,597**

	For the nine months ended 31 March 2025			
	Attributable to owner of the Company			
In Taka	**Share capital**	**Revaluation reserve**	**Retained earnings**	**Total**
Balance at 1 July 2024	472,500	1,442,196	1,345,681	3,260,377
Total comprehensive income				
Profit for the period	-	-	406,442	406,442
Total comprehensive income	-	-	406,442	406,442
Transactions with owners of the company	-	-	-	-
Contributions and distributions				
Dividends	-	-	(94,500)	(94,500)
Total transactions with owners of the company	-	-	(94,500)	(94,500)
Balance at 31 March 2025	472,500	1,442,196	1,657,623	3,572,319

ACI Formulations PLC

Statement of cash flows
Unaudited

Figures in "000"

In Taka	Note	For the nine months ended from July 2025 to March 2026	July 2024 to March 2025
Cash flows from operating activities			
Cash received from customers and others		3,659,022	3,698,275
Cash paid to suppliers and employees		(3,738,803)	(3,247,571)
Cash (used in)/generated from operating activities		**(79,780)**	**450,703**
Paid to WPPF		(25,881)	(22,605)
Interest paid		(94,677)	(132,963)
Income tax paid		(125,846)	(130,653)
		(246,403)	**(286,220)**
Net cash (used in)/generated from operating activities*	20	**(326,183)**	**164,483**
Cash flows from investing activities			
Acquisition of property, plant and equipment		(173,138)	(58,256)
Sales proceed from disposal		967	7,339
Investment		353	-
Net cash (used in)/generated from investing activities		**(171,818)**	**(50,917)**
Cash flows from financing activities			
Inter-company debts received/(paid)		136,929	(704,401)
Proceeds from loans and borrowings		412,866	709,706
Payment for lease liability		(13,485)	(10,232)
Dividends paid		(117,779)	(94,190)
Net cash (used in)/generated from financing activities		**418,531**	**(99,118)**
Net (decrease)/increase in cash and cash equivalents		**(79,471)**	**14,449**
Cash and cash equivalents as at 1 July		(2,478)	(390)
Cash and cash equivalents as at 31 March		**(81,949)**	**14,058**
Closing balance represents			
Cash and cash equivalents		42,905	128,076
Bank overdraft		(124,854)	(114,018)
		(81,949)	**14,058**
Net operating cash flow per share (NOCFPS)		**(6.90)**	**3.48**

* See Note 20 for reconciliation of net operating cash flow.

ACI Formulations PLC

Consolidated Statement of Financial Position
Unaudited

Figures in "000"

In Taka	Note	As at 31 March 2026	As at 30 June 2025
Assets			
Property, plant and equipment	5(a)	2,796,608	2,662,177
Right-of-use assets		21,668	23,291
Investments	6(a)	61,957	61,604
Intangible assets	7	5,148	5,148
Non-current assets		**2,885,381**	**2,752,220**
Inventories	8(a)	1,563,765	1,469,898
Trade receivables	9(a)	2,149,047	1,320,125
Other receivables		162,130	63,685
Inter-company receivable	10(a)	1,914,295	2,046,816
Advances, deposits and prepayments	11(a)	158,362	202,407
Current tax assets		485,180	485,296
Cash and cash equivalents		43,719	244,488
Current assets		**6,476,497**	**5,832,716**
Total assets		**9,361,878**	**8,584,935**
Equity			
Share capital		472,500	472,500
Revaluation reserve		1,475,889	1,475,889
Retained earnings		1,891,435	1,619,234
Equity attributable to the owner of the Company		**3,839,824**	**3,567,623**
Non controlling interest		**2,404**	**2,182**
Total equity		**3,842,228**	**3,569,806**
Liabilities			
Employee benefits	12	54,976	67,965
Lease liabilities		28,701	29,331
Deferred tax liabilities		198,876	199,583
Non-current liabilities		**282,553**	**296,879**
Bank overdrafts		124,854	245,034
Loans and borrowings		4,055,920	3,643,054
Lease liabilities- current portion		21,527	13,157
Trade payables		118,123	163,743
Other payables	13(a)	914,628	651,564
Unclaimed dividend account	14	2,044	1,699
Current liabilities		**5,237,097**	**4,718,251**
Total liabilities		**5,519,650**	**5,015,130**
Total equity and liabilities		**9,361,878**	**8,584,935**
Net asset value (NAV) per share	21	**81.27**	**75.51**

Managing Director | **Director** | **Chief Financial Officer** | **Company Secretary**

ACI Formulations PLC

Consolidated statement of profit or loss and other comprehensive income
Unaudited

Figures in "000"

In Taka	Note	For the nine months ended from July 2025 to March 2026	For the nine months ended from July 2024 to March 2025	For the 3rd quarter ended from January 2026 to March 2026	For the 3rd quarter ended from January 2025 to March 2025
Revenue	16(a)	**4,526,609**	4,123,294	**1,359,803**	1,300,070
Cost of sales	17(a)	**(3,090,553)**	(2,737,639)	**(951,163)**	(907,509)
Gross profit		**1,436,056**	1,385,656	**408,640**	392,561
Administrative, selling and distribution expenses	18(a)	**(767,386)**	(649,365)	**(258,477)**	(226,844)
Other income	19	**61,551**	38,521	**24,195**	5,329
Operating profit		**730,221**	774,812	**174,358**	171,047
Finance costs, net		**(187,604)**	(209,088)	**(66,815)**	(57,234)
Profit before contribution to WPPF		**542,617**	565,724	**107,543**	113,812
Contribution to WPPF		**(26,814)**	(28,132)	**(5,284)**	(5,647)
Profit before tax		**515,803**	537,592	**102,259**	108,165
Income tax expenses		**(125,255)**	(128,932)	**(18,933)**	(18,736)
Profit after tax		**390,547**	408,660	**83,326**	**89,429**
Other comprehensive income		**-**	-	**-**	-
Total comprehensive income		**390,547**	**408,660**	**83,326**	**89,429**
Total comprehensive income attributable to:					
Owners of the Company		**390,326**	**408,512**	**83,260**	89,401
Non controlling interest		**222**	148	**67**	28
		390,547	**408,660**	**83,326**	**89,429**
Earnings per share					
Basic earnings per share (EPS)	21	**8.26**	**8.65**	**1.76**	**1.89**

Managing Director | **Director** | **Chief Financial Officer** | **Company Secretary**

ACI Formulations PLC

Consolidated statement of changes in equity
Unaudited

Figures in "000"

For the nine months ended 31 March 2026

In Taka	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2025	472,500	1,475,889	1,619,234	3,567,623	2,182	3,569,806
Total comprehensive income						
Profit for the period	-	-	390,326	390,326	222	390,547
Total comprehensive income	-	-	390,326	390,326	222	390,547
Transactions with owners of the company						
Contributions and distributions						
Dividends	-	-	(118,125)	(118,125)	-	(118,125)
Total transactions with owners of the company	-	-	(118,125)	(118,125)	-	(118,125)
Balance at 31 March 2026	472,500	1,475,889	1,891,435	3,839,824	2,404	3,842,228

For the nine months ended 31 March 2025

In Taka	Attributable to owner of the Company				Non-controlling interests	Total equity
	Share capital	Revaluation reserve	Retained earnings	Total		
Balance at 1 July 2024	472,500	1,442,196	1,342,956	3,257,653	1,985	3,259,637
Total comprehensive income						
Profit for the period	-	-	408,512	408,512	148	408,660
Total comprehensive income	-	-	408,512	408,512	148	408,660
Transactions with owners of the company						
Contributions and distributions						
Dividends	-	-	(94,500)	(94,500)	-	(94,500)
Total transactions with owners of the company	-	-	(94,500)	(94,500)	-	(94,500)
Balance at 31 March 2025	472,500	1,442,196	1,656,968	3,571,664	2,133	3,573,797

ACI Formulations PLC

Consolidated statement of cash flows
Unaudited

Figures in "000"

In Taka	Note	For the nine months ended from July 2025 to March 2026	July 2024 to March 2025
Cash flows from operating activities			
Cash received from customers and others		3,664,050	3,700,552
Cash paid to suppliers and employees		(3,739,066)	(3,248,017)
Cash (used in)/generated from operating activities		**(75,016)**	**452,535**
Paid to WPPF		(25,881)	(22,605)
Interest paid		(93,197)	(131,508)
Income tax paid		(126,792)	(131,730)
		(245,870)	**(285,842)**
Net cash (used in)/generated from operating activities*	**20 (a)**	**(320,886)**	**166,693**
Cash flows from investing activities			
Acquisition of property, plant and equipment		(173,138)	(58,256)
Sales proceed from disposal		967	7,339
Investment		353	-
Net cash (used in)/generated from investing activities		**(171,818)**	**(50,917)**
Cash flows from financing activities			
Inter-company debts received/(paid)		130,513	(708,200)
Proceeds from loans and borrowings		412,866	709,706
Payment for lease liability		(13,485)	(10,232)
Dividends paid		(117,779)	(94,190)
Net cash (used in)/generated from financing activities		**412,115**	**(102,916)**
Net (decrease)/increase in cash and cash equivalents		(80,589)	12,859
Cash and cash equivalents as at 1 July		**(546)**	**2,638**
Cash and cash equivalents as at 31 March		**(81,135)**	**15,497**
Closing balance represents			
Cash and cash equivalents		43,719	129,516
Bank overdraft		(124,854)	(114,018)
		(81,135)	**15,497**
Net operating cash flow per share (NOCFPS)	21	**(6.79)**	**3.53**

* See Note 20(a) for reconciliation of consolidated net operating cash flow.

ACI Formulations PLC

Notes to the financial statements
as at and for the nine months ended on 31 March 2026
Unaudited

1 Company profile:

ACI Formulations PLC, a subsidiary of Advanced Chemical Industries PLC, domiciled in Bangladesh. The company's shares are listed with both Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited. The Principal activities of the company are manufacturing and marketing of a number of agrochemical, consumer brand and paint products.

2 Subsidiaries of ACI Formulations PLC:

Neem Laboratories (Pvt.) Ltd.
Neem Laboratories (Pvt.) Ltd generate its revenue through royalty fees based on the agreement with ACI PLC effective from 1 July 2019 ; the later currently being engaged in the manufacturing of products under the Neem brand name. Since the Subsidiary showed profitability during the year, its ability to operate as a going concern is not at risk. ACI Formulations PLC through its voting rights controls the operating and financing activities of this entity.

ACI AgroChem (Pvt.) Ltd.
ACI AgroChem was incorporated on 22nd June 2022 as a limited Company. The principal activities of the Company is to manufacture and marketing of various kinds of agricultural input like chemical including other allied and general chemical. The Company is yet to start its operation. ACI Formulations PLC through its voting rights (90% share holdings of ACI AgroChem Limited) controls the operating and financing activities of this entity.

3 Consolidated Financial statements:

In addition to the separate financial statements, the consolidated financial statements of the company have been prepared and included in this interim financial report as per IFRS 10: Consolidated Financial Statements. In separate Financial Statements, investment in subsidiaries has been carried at cost as per IAS 27: Separate Financial Statements.

4 Selected explanatory notes:
These financial statements have been prepared in line with Accounting Policies as adopted in the preparation of financial statements for the year ended 30 June 2025. This interim financial report includes only those selected explanatory notes as were deemed appropriate for better understanding of unaudited financial statements.

		Figures in '000'
	31- Mar -26 Taka	30-June -25 Taka
5 Property, plant & equipment		
Opening balance	**3,137,478**	2,979,040
Addition during the period	**173,564**	173,443
Adjustment/disposal during the period	**-**	(11,306)
	3,311,042	3,141,178
Accumulated depreciation at the end of period	**(514,434)**	(479,009)
Closing balance	**2,796,608**	2,662,168

		31- Mar -26	30-June -25
		Taka	Taka
5(a)	**Consolidated property, plant & equipment**		
	Opening balance	**3,141,186**	2,979,049
	Addition during the period	**173,564**	173,443
	Adjustment/disposal during the period	**-**	(11,306)
		3,314,750	3,141,186
	Accumulated depreciation at the end of period	**(518,142)**	(479,009)
	Closing balance	**2,796,608**	2,662,177
6	**Investments**		
	Investment in subsidiaries	**21,948**	21,948
	Investment in FDR	**61,882**	61,529
	Investment in shares of ACI Motors Limited	**75**	75
		83,905	83,552
6(a)	**Consolidated investments**		
	Investment in FDR	**61,882**	61,529
	Investment in Shares- ACI Motors Limited	**75**	75
		61,957	61,604
7	**Intangible assets**		
	Goodwill on acquisition :		
	Neem Laboratories (Pvt.) Limited	**5,148**	5,148
		5,148	5,148
8	**Inventories**		
	Raw and packing materials	**770,690**	546,150
	Finished goods	**740,799**	618,605
	Goods in transit	**64,242**	310,761
	Other inventories	**18,960**	26,586
	Allowances for slow moving inventory	**(30,926)**	(32,204)
		1,563,765	1,469,898
8(a)	**Consolidated inventories**		
	Raw and packing materials	**770,690**	546,150
	Finished goods	**741,075**	618,882
	Goods in transit	**64,242**	310,761
	Other inventories	**18,960**	26,586
	Allowances for slow moving inventory	**(31,202)**	(32,480)
		1,563,765	1,469,898
9	**Trade receivables**		
	Related parties	**-**	7,094
	Other than related parties	**2,405,918**	1,566,156
		2,405,918	1,573,249
	Allowances for doubtful debts	**(258,624)**	(254,897)
		2,147,294	1,318,352
	Below six months	**1,905,489**	1,057,170
	Over six months	**500,429**	516,080
	Allowances for doubtful debts	**(258,624)**	(254,897)
		2,147,294	1,318,352
9(a)	**Consolidated trade receivables**		
	Related parties	**-**	7,094
	Other than related parties	**2,407,671**	1,567,929
		2,407,671	1,575,022
	Allowances for doubtful debts	**(258,624)**	(254,897)
		2,149,047	1,320,125
	Below six months	**1,905,916**	1,057,597
	Over six months	**501,755**	517,425
	Allowances for doubtful debts	**(258,624)**	(254,897)
		2,149,047	1,320,125

		31- Mar -26 Taka	30-June -25 Taka
10	**Inter-company receivables**		
	Advanced Chemical Industries PLC	**1,849,937**	1,990,274
	ACI HealthCare Bangladesh Ltd.	**56,212**	53,333
	Neem Laboratories (Pvt.) Ltd.	**7,198**	7,198
		1,913,348	2,050,805
10(a)	**Consolidated inter-company receivables**		
	Advanced Chemical Industries PLC	**1,858,082**	1,993,483
	ACI HealthCare USA Inc.	**56,212**	53,333
		1,914,295	2,046,816
11	**Advances, deposits & prepayments**		
	Advances:		
	Staffs	**231**	9
	Suppliers & others	**19,369**	15,424
	VAT current account	**25,845**	24,965
		45,445	40,399
	Deposits:		
	Security deposits	**16,659**	10,146
	LC Margin	**84,656**	147,557
	Bank guarantee margin	**6,409**	2,339
		107,724	160,042
	Prepayments:		
	Prepaid expenses	**4,738**	1,602
		4,738	1,602
		157,907	202,043
11(a)	**Consolidated advances, deposits & prepayments**		
	Advances:		
	Staff	**231**	9
	Suppliers & others	**19,824**	15,789
	VAT current account	**25,845**	24,965
		45,900	40,763
	Deposits:		
	Security deposits	**16,659**	10,146
	LC Margin	**84,656**	147,557
	Bank guarantee margin	**6,409**	2,339
		107,724	160,042
	Prepayments:		
	Prepaid expenses	**4,738**	1,602
		4,738	1,602
		158,362	202,407
12	**Employee benefits**		
	Defined benefit obligation	**34,899**	48,337
	Other employee benefits	**20,078**	19,628
		54,976	67,965
13	**Other payables**		
	Creditor for expenses	**487,652**	384,702
	Advance from customer	**8,078**	18,753
	Interest payable	**189,901**	95,495
	Security money payable	**182,364**	107,207
	Withholding tax and VAT payable	**19,851**	19,537
	Workers' profit participation fund	**26,498**	25,564
		914,343	651,258

		31- Mar -26 Taka	30-June -25 Taka
13(a)	**Consolidated other payables**		
	Creditor for expenses	**487,937**	385,008
	Advance from customer	**8,078**	18,753
	Interest payable	**189,901**	95,495
	Security money payable	**182,364**	107,207
	Withholding tax and VAT payable	**19,851**	19,537
	Provision for workers' profit participation fund	**26,498**	25,564
		914,628	651,564
14	**Unclaimed dividend account**		
	Unclaimed/ unpaid dividend	**2,044**	1,699
		2,044	1,699
15	**Inter-company payables**		
	ACI AgroChem Limited	**21,843**	22,372
		21,843	22,372

		for the period from	
		July 2025 to March 2026 Taka	July 2024 to March 2025 Taka
16	**Revenue**		
	Crop Care & Public Health	**3,520,076**	3,220,412
	Mosquito Coil	**-**	1,231
	Aerosol	**581,166**	534,900
	Paint	**416,138**	356,018
	Others	**4,222**	8,640
		4,521,602	4,121,201
16(a)	**Consolidated revenue**		
	Crop Care & Public Health	**3,520,076**	3,220,412
	Mosquito Coil	**-**	1,231
	Aerosol	**581,166**	534,900
	Paint	**416,138**	356,018
	Others	**9,229**	10,733
		4,526,609	4,123,294

		for the period from	
		July 2025 to March 2026	July 2024 to March 2025
		Taka	Taka
17	**Cost of sales**		
	Opening stock	**1,164,755**	1,143,347
	Purchase	**3,256,449**	2,515,532
	Stock write off	**(191)**	6,548
		4,421,013	3,665,427
	Closing stock	**(1,511,488)**	(1,091,621)
		2,909,525	2,573,806
	Manufacturing expenses	**181,029**	163,832
		3,090,553	2,737,639
17(a)	**Consolidated cost of sales**		
	Opening stock	**1,164,755**	1,143,347
	Purchase	**3,256,449**	2,515,532
	Stock write off	**(191)**	6,548
		4,421,013	3,665,427
	Closing stock	**(1,511,488)**	(1,091,621)
		2,909,525	2,573,806
	Manufacturing expenses	**181,029**	163,832
		3,090,553	2,737,639
18	**Administrative, selling and distribution expenses**		
	Administrative expenses	**218,531**	168,103
	Distribution expenses	**114,855**	96,061
	Selling expenses	**433,841**	384,739
		767,227	648,903
18(a)	**Consolidated administrative, selling and distribution expenses**		
	Administrative expenses	**218,690**	168,565
	Distribution expenses	**114,855**	96,061
	Selling expenses	**433,841**	384,739
		767,386	649,365
19	**Other income**		
	Sales of Scrap	**11,773**	8,358
	Dividend Income	**47,317**	20,753
	Rental Income	**1,464**	1,750
	Miscellaneous Income	**29**	150
	Gain/loss on disposal	**967**	6,241
	Unrealized gain/(loss) on translation of foreign currency receivable	**-**	1,269
		61,551	38,521

20 Reconciliation of net operating cash flow

	for the period from	
In Taka	July 2025 to March 2026	July 2024 to March 2025
Profit after tax	**385,830**	406,442
Adjustment for non cash items and others:		
- Depreciation and amortization	**38,698**	34,610
- Provisions	**7,270**	16,026
- Net finance cost	**94,407**	77,580
- Unrealized gain/(loss) on translation of foreign currency receivables	**-**	(1,269)
- Tax expense	**(2,201)**	(2,589)
- Contribution to WPPF	**934**	5,527
- Gain/ loss on asset disposal	**(967)**	(6,241)
- Dividend income	**(47,317)**	(20,753)
Changes in:		
- Inventories	**(92,780)**	157,076
- Trade and other receivables	**(931,703)**	(471,232)
- Advances, deposit and prepayments	**44,136**	42,987
- Trade and other payables, employment benefits' and others	**177,509**	(73,679)
Cash generating from operating activities	**(326,183)**	164,483

20 (a) Reconciliation of consolidated net operating cash flow

In Taka	for the period from July 2025 to March 2026	July 2024 to March 2025
Profit after tax	**390,547**	408,660
Adjustment for:		
- Depreciation and amortization	**38,698**	34,628
- Bad debts and inventory loss/(recovery)	**7,270**	16,026
- Net finance cost	**94,407**	77,580
- Unrealized gain/(loss) on translation of foreign currency receivables	**-**	(1,269)
- Tax expense	**(1,966)**	(2,272)
- Contribution to WPPF	**934**	5,527
- Gain/ loss on asset disposal	**(967)**	(6,241)
- Dividend income	**(47,317)**	(20,753)
Changes in:		
- Inventories	**(92,780)**	157,076
- Trade and other receivables	**(931,771)**	(470,950)
- Advances, deposit and prepayments	**44,045**	43,053
- Trade and other payables, employment benefits' and others	**178,013**	(74,371)
Cash generating from operating activities	**(320,886)**	166,693

	for the period upto July 2025 to March 2026	July 2024 to March 2025
21 Consolidated EPS, NAV per Share and NOCFPS:		
Weighted average number of ordinary shares (in thousand)	**47,250**	47,250
Consolidated profit attributable to equity holders of the Company (Taka '000)	**390,326**	408,512
Earnings per share (Taka)	**8.26**	8.65
Consolidated cash flows from operating activities (Taka '000)	**(320,886)**	166,693
Net operating cash flows per share (NOCFPS)	**(6.79)**	3.53
	31- Mar -26 Taka	**30-June -25 Taka**
Consolidated net asset attributable to equity holders of the Company (Taka '000)	**3,839,824**	3,567,623
Net asset value (NAV) per share	**81.27**	75.51

Consolidated revenue of first nine months increased by around 9.78% over Same Period Last Year (SPLY) and GP growth of 3.64% is impacted by the higher price of raw material and packing material in the international market. While operating expenses rose by 18.17%, driven by inflationery adjustments, transportation costs of export and demand-generating activities; financing costs decreased due to the efficient utilization of working capital and other income has increased.Consequently, consolidated profit after tax during Jul 25 to Mar 26 stood at Tk. 390.55 Mn against Tk 408.66 Mn of SPLY resulting in lower consolidated EPS. However, NAV per share has increased. On the other hand, consolidated NOCFPS decreased due to lower collections and suppliers payment.

22 Segment reporting

The Company has four reportable segments, as described below, which are the Company's strategic divisions. The strategic divisions offer different products and services, and are managed separately because they require different technology and marketing strategies. For each of the strategic divisions, the Company's CEO reviews internal management reports at least on a quarterly basis. The following summary describes the operations in each of the Company's reportable segments:

Crop Care and Public Health (CC & PH)	To manufacture and sell crop care and public health products.
Mosquito Coil (M Coil)	To manufacture and sell mosquito coil products
Aerosol	To manufacture and sell aerosol and air freshener products.
Paint	To manufacture and sell of paint products.

Figures in '000'

Particulars	CC &PH		M Coil		Aerosol		Paint		Unallocated		Total	
	For the nine months ended on		For the nine months ended on		For the nine months		For the nine months		For the nine months		For the nine months ended on	
	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25	31-Mar-26	31-Mar-25
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
Segment revenue:												
External revenues	**3,520,076**	3,220,412	**-**	1,231	**581,166**	533,817	**416,138**	356,018	**4,222**	8,640	**4,521,602**	4,120,117
Inter-segment revenues	**-**	-	**-**	-	**-**	1,084			**5,007**	2,093	**5,007**	3,177
Total revenue	**3,520,076**	3,220,412	**-**	1,231	**581,166**	534,900	**416,138**	356,018	**9,229**	10,733	**4,526,609**	4,123,294
Financing costs	**(148,717)**	(158,221)	**-**	(147)	**(11,615)**	(25,321)	**(35,435)**	(23,730)	**8,163**	(1,668)	**(187,604)**	(209,088)
Depreciation	**(24,479)**	(18,449)	**(5,297)**	(8,325)	**(4,407)**	(4,022)	**(3,693)**	(3,218)	**(822)**	(595)	**(38,698)**	(34,610)
Cost of sales excluding depreciation	**(2,151,974)**	(1,901,194)	**(9,192)**	(13,921)	**(561,538)**	(500,078)	**(333,374)**	(281,580)	**(11,235)**	(17,149)	**(3,067,313)**	(2,713,921)
Operating expenses excluding depreciation	**(612,576)**	(515,952)	**(625)**	(6,861)	**(12,215)**	(9,470)	**(124,813)**	(108,578)	**(1,698)**	(2,494)	**(751,926)**	(643,355)
Other income /(expense)	**11,043**	13,074	**2,919**	7,287	**29**	803	**150**	-	**47,410**	17,357	**61,551**	38,521
Profit before tax	**564,001**	607,686	**(11,591)**	(19,700)	**(8,155)**	(3,028)	**(77,016)**	(58,034)	**51,048**	5,875	**515,803**	**537,592**
Reportable segment assets	**4,240,013**	3,316,182	**148,501**	166,515	**602,323**	662,489	**648,088**	639,036	**3,722,952**	3,800,713	**9,361,878**	**8,584,935**
Reportable segment liabilities	**2,106,140**	1,669,320	**14,197**	14,373	**165,433**	272,227	**162,010**	172,704	**3,071,869**	2,886,506	**5,519,650**	**5,015,130**

*** Comparative figures of segment assets and segment liabilities are as of 30 June 2025.**

23 Figures have been rounded off to the nearest '000' Taka and previous period's figures have been rearranged to conform to current period's presentation.